Gilead Sciences

Gilead Sciences: Carbon Emissions and Climate Commitments

Gilead Sciences, headquartered in the US and operating in the Pharmaceutical Preparation Manufacturing industry, has established ambitious targets for reducing its greenhouse gas (GHG) emissions.

Emissions Overview (in kg CO2e):

• 2024: Total emissions were approximately 1.07 billion kg CO2e. This includes Scope 1 emissions of approximately 53.86 million kg CO2e, Scope 2 emissions (market-based) of approximately 17.14 million kg CO2e, and Scope 3 emissions of approximately 998.1 million kg CO2e.
• 2023: Total emissions were approximately 1.71 billion kg CO2e. Scope 1 emissions were approximately 564.35 million kg CO2e, Scope 2 (market-based) were approximately 226.03 million kg CO2e, and Scope 3 were approximately 1.15 billion kg CO2e.
• 2022: Total emissions were approximately 1.25 billion kg CO2e. Scope 1 emissions amounted to approximately 55.92 million kg CO2e, Scope 2 (market-based) were approximately 26.29 million kg CO2e, and Scope 3 were approximately 1.20 billion kg CO2e.
• 2021: Total emissions were approximately 1.09 billion kg CO2e. Scope 1 emissions were approximately 55.10 million kg CO2e, Scope 2 (market-based) were approximately 34.30 million kg CO2e, and Scope 3 were approximately 1.03 billion kg CO2e.
• 2020: Total emissions were approximately 1.25 billion kg CO2e. Scope 1 emissions were approximately 48.63 million kg CO2e, Scope 2 (market-based) were approximately 32.13 million kg CO2e, and Scope 3 were approximately 1.15 billion kg CO2e.
• 2019: Total emissions were approximately 1.15 billion kg CO2e. Scope 1 emissions were approximately 54.10 million kg CO2e, Scope 2 (market-based) were approximately 33.33 million kg CO2e, and Scope 3 were approximately 1.09 billion kg CO2e.
• 2018: Scope 1 emissions were approximately 46.70 million kg CO2e and Scope 2 (market-based) were approximately 25.59 million kg CO2e. Scope 3 data was not disclosed for this year.
• 2017: Scope 1 emissions were approximately 46.69 million kg CO2e and Scope 2 (market-based) were approximately 29.13 million kg CO2e. Scope 3 data was not disclosed for this year.
• 2016: Scope 1 emissions were approximately 44.75 million kg CO2e and Scope 2 (market-based) were approximately 36.81 million kg CO2e. Scope 3 data was not disclosed for this year.

Climate Commitments and Reduction Targets:

Gilead Sciences is committed to significant GHG emission reductions, with targets aligned with the Science Based Targets initiative (SBTi).

• Scope 1 and 2 Emissions: The company has committed to reducing absolute Scope 1 and 2 GHG emissions by 46% by 2030, using a 2019 baseline year. This target is consistent with reductions required to limit warming to 1.5°C. Gilead also aims for carbon net-zero operational GHG emissions by 2030.
• Scope 3 Emissions: Gilead Sciences has set a target to reduce absolute Scope 3 GHG emissions by 15% by 2030, also from a 2019 baseline.

Key Reduction Initiatives:

• 2025 Target (Previously): Previously, Gilead had a goal to reduce Scope 1 and 2 emissions by 25% by 2025, compared to a 2016 baseline.
• Net-Zero Ambition: The company has a net-zero operations ambition for Scope 1 and 2 by 2030.

These commitments highlight Gilead Sciences' focus on mitigating its environmental impact within the pharmaceutical sector.